ethyl 17-[[(4-methylbenzene)sulfonyl]oxy]-3,6,9,12,15-pentaoxaheptadecanoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 17-[[(4-methylbenzene)sulfonyl]oxy]-3,6,9,12,15-pentaoxaheptadecanoate
• 英文别名: ethyl 17-(tosyloxy)-3,6,9,12,15-pentaoxaheptadecan-1-oate；Ethyl 2-[2-[2-[2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetate
• 化学式: C₂₁H₃₄O₁₀S
• 分子量: 478.561
• InChiKey: TZFGCBPAQWCBNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  32
• 可旋转键数：
  21
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  124
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  ethyl 17-[[(4-methylbenzene)sulfonyl]oxy]-3,6,9,12,15-pentaoxaheptadecanoate 在 lithium hydroxide monohydrate 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  아토르바스타틴 유래의 HMG-CoA 환원효소 분해 유도 화합물

  摘要：

  该专利涉及HMG-CoA还原酶降解诱导化合物。具体而言，该专利涉及一种将阿托伐他汀和E3泛素连接酶结合物连接在一起的化学连接剂的功能性化合物，其用作HMG-CoA还原酶的分解方法，以及用于预防或治疗与HMG-CoA还原酶相关疾病的药学组合物的制备方法。

  公开号：

  KR102160377B1
• 作为产物：
  描述：

  羟丙基淀粉磷酸酯 在 吡啶 、 dirhodium tetraacetate 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 生成 ethyl 17-[[(4-methylbenzene)sulfonyl]oxy]-3,6,9,12,15-pentaoxaheptadecanoate
  参考文献：
  名称：

  아토르바스타틴 유래의 HMG-CoA 환원효소 분해 유도 화합물

  摘要：

  该专利涉及HMG-CoA还原酶降解诱导化合物。具体而言，该专利涉及一种将阿托伐他汀和E3泛素连接酶结合物连接在一起的化学连接剂的功能性化合物，其用作HMG-CoA还原酶的分解方法，以及用于预防或治疗与HMG-CoA还原酶相关疾病的药学组合物的制备方法。

  公开号：

  KR102160377B1

文献信息

• [EN] INHIBITORS OF CYCLIN-DEPENDENT KINASES AND USES THEREOF<br/>[FR] INHIBITEURS DE KINASES DÉPENDANTES DES CYCLINES ET LEURS UTILISATIONS
  申请人：LES LABORATOIRES SERVIER SAS

  公开号：WO2021155006A1

  公开（公告）日：2021-08-05

  Provided are novel compounds of Formula (I); pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by CDK such as cancer.

  提供了式（I）的新化合物；其药用盐，以及药物组合物，可用于治疗由CDK介导的癌症等疾病和疾病。
• Process for the production of perbenzylated 1-O-glycosides
  申请人：——

  公开号：US20030055242A1

  公开（公告）日：2003-03-20

  The invention relates to a process for the production of perbenzylated 1-O-glycosides of general formula I or salts thereof 1 in which sugar 1 is a monosaccharide that is functionalized in 1-OH-position, R represents benzyl, n means 2, 3 or 4, X means —COO— or —NH— and L means a straight-chain, branched, saturated or unsaturated C 1 -C 30 carbon chain, which optionally is interrupted or substituted by groups. The process according to the invention starts from economical starting materials, provides good yields and allows the production of perbenzylated saccharides with 1-O-functionalized side chains on an industrial scale.

  该发明涉及一种生产通式I的过苄基化1-O-糖苷或其盐的方法，其中糖1是在1-OH位置上官能化的单糖，R代表苄基，n为2、3或4，X代表—COO—或—NH—，L代表直链、支链、饱和或不饱和的C1-C30碳链，该碳链可以选择性地被基团中断或取代。根据该发明的方法从经济起始材料开始，提供良好的产率，并允许在工业规模上生产具有1-O官能化侧链的过苄基化糖类。
• Process for the production of perbenzylated 1-0-glycosides
  申请人：SCHERING AKTIENGESELLSCHAFT

  公开号：US20020002274A1

  公开（公告）日：2002-01-03

  The invention relates to a process for the production of perbenzylated 1-O-glycosides of general formula I or salts thereof 1 in which sugar 1 is a monosaccharide that is functionalized in 1 -OH-position, R represents benzyl, n means 2, 3 or 4, means —O—, —S—, —COO— or —NH— and L means a straight-chain, branched, saturated or unsaturated C 1 -C 30 carbon chain, which optionally is interrupted or substituted by groups. The process according to the invention starts from economical starting materials, provides good yields and allows the production of perbenzylated saccharides with 1-O-functionalized side chains on an enlarged scale.

  本发明涉及一种生产通式I的1-O-苄基化糖苷或其盐的过程，其中糖1是在1-OH位置上官能化的单糖，R代表苄基，n为2、3或4，代表-O、S、COO或NH，L代表直链、支链、饱和或不饱和的C1-C30碳链，该碳链可以被中断或取代。本发明的过程从经济实惠的起始材料开始，提供良好的产量，并允许在扩大规模上生产1-O官能化侧链的苄基化糖苷。
• EGFR proteolysis targeting chimeric molecules and associated methods of use
  申请人：Arvinas Operations, Inc.

  公开号：US10994015B2

  公开（公告）日：2021-05-04

  The present disclosure relates to bifunctional compounds, which find utility as modulators of receptor tyrosine kinase (RTK) proteins. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand which binds to an E3 ubiquitin ligase and on the other end a moiety which binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effectuate ubiquitination, and therefore, degradation (and inhibition) of the target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，它们可用作受体酪氨酸激酶（RTK）蛋白的调节剂。特别是，本公开涉及双功能化合物，其一端含有与 E3 泛素连接酶结合的配体，另一端含有与靶蛋白结合的分子，从而使靶蛋白靠近泛素连接酶以实现泛素化，进而降解（和抑制）靶蛋白。本公开内容展示了与靶蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物可以治疗或预防因目标蛋白聚集或积聚而导致的疾病或失调。
• Atorvastatin derived HMG-CoA reductase degradation inducing compound
  申请人：UPPTHERA

  公开号：US11066391B1

  公开（公告）日：2021-07-20

  The present invention relates to bifunctional compounds that induce HMG-CoA reductase degradation, in which in which atorvastatin and E3 ubiquitin ligase binding moiety are chemically linked. The present invention also relates to a preparation method of the compounds, a method for degrading HMG-CoA reductase using the compounds, and a composition for the prevention or treatment of HMG-CoA reductase-related diseases comprising the compounds.

  本发明涉及诱导HMG-CoA还原酶降解的双功能化合物，其中阿托伐他汀和E3泛素连接酶结合分子通过化学连接。本发明还涉及该化合物的制备方法、使用该化合物降解HMG-CoA还原酶的方法，以及包含该化合物的用于预防或治疗HMG-CoA还原酶相关疾病的组合物。